jls57
![]()
Posts:22
My mom is looking into the Phase 1 clinical trial of the drug ASP 8273(third generation TKI). She is EGFR+ with a 19 deletion and T790M -. I am aware that this trial has only been open since April but is there any early indications that this drug might be effective for T790M negative patients or is it designed to be more effective for patients with T790M? Any common side effects?
Thank you!
Forums
Reply # - October 6, 2014, 09:00 PM
This agent is still in dose
This agent is still in dose escalation testing, so there are no results yet available on its efficacy or really even its tolerability. With the dose escalation, side effects are still being defined, and no prohibitive side effects have been seen yet, but it's too early to say almost anything.
Good luck.
-Dr. West
Reply # - October 8, 2014, 12:27 PM
Thank you, Dr. west!
Thank you, Dr. west!
Reply # - October 27, 2014, 02:45 PM
Hello,
Hello,
Is it possible for a third generation TKI to cause a pseudo- progression when it is first started?
Thank you
Reply # - October 27, 2014, 03:28 PM
Hi jls57,
Hi jls57,
Dr. West commented on a question very close to yours though he leaves open the possibility of recent onset of treatment. "With patients receiving immune-based therapy, we now sometimes see areas of known cancer enlarge before they shrink later, and if they are biopsied, enlarged nodules can just show a robust immune response. This is increasingly recognized and is known as “pseudoprogression”. So that can certainly happen in patients on immunotherapy for cancer, but I’d have to confess that I think this is extremely unlikely that a cancer treated with standard chemo or an EGFR inhibitor like Iressa (gefitinib) or Tarceva (erlotinib) would enlarge due to inflammation, especially if treatment hadn’t just been initiated." http://cancergrace.org/topic/still-surfin-in-ds-wake-but-board-is-crack…
I've asked one of our faculty to comment and will certainly get her input given she's available.
Much hope,
Janine
Reply # - October 27, 2014, 04:27 PM
Hi jls57
Hi jls57
i would have to agree with Janine on this, we do see flair reactions or pseudoprogressions to immune agents but i have never seen one with any of the EGFR directed therapies, even the newest ones.
best of luck,
Dr Laskin